VENUS REMEDIES LTD.

Venus Remedies Ltd has announced the closure of its trading window for all designated persons and their immediate relatives. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will remain shut from October 1, 2026, until 48 hours after the declaration of the unaudited financial results for the period ending September 30, 2026. This action is a standard procedure to prevent potential insider trading activities around financial result announcements.

Venus Remedies Limited has announced a special window for the re-lodgement of transfer requests for physical shares. This initiative is in accordance with SEBI guidelines dated July 02, 2025, and January 30, 2026. The company has provided links to its social media handles (Facebook, Instagram, LinkedIn, X) where shareholders can find more information. This move aims to facilitate the transfer process for shareholders holding physical shares and ensure compliance with regulatory requirements.

Venus Remedies Ltd announced that its members approved the alteration of its Memorandum and Articles of Association (MOA/AOA) during the Annual General Meeting (AGM) held on August 20, 2026. The revisions to the MOA aim to align the object clause with the Companies Act, 2013, and update it to reflect current and proposed business activities in the pharmaceutical sector. The new Articles of Association are adopted as per Table-F of Schedule I of the Companies Act, 2013. The company's principal business activities in the pharmaceutical sector remain unchanged.

Venus Remedies Ltd announced that its 37th Annual General Meeting (AGM) held on August 20, 2026, saw the approval of several director appointments and re-appointments. Mr. Saransh Chaudhary was appointed as an Executive Director, and Dr. Gurminder Singh Bedi as a Non-Executive Independent Director, both for five-year terms starting May 26, 2026. Additionally, Dr. (Mrs.) Manu Chaudhary was re-appointed as Joint Managing Director, and Dr. (Mrs.) Savita Gupta as Non-Executive Independent Director, for five-year terms commencing October 1, 2026, and December 29, 2026, respectively. The company will submit voting results and the scrutinizer's report to the stock exchanges within the prescribed timelines.

Venus Remedies Ltd has announced its 37th Annual General Meeting (AGM) will be held on Thursday, August 20, 2026, at 11:30 AM IST via Video Conferencing/Other Audio Visual Means. The company is submitting its Annual Report and AGM Notice for FY 2025-26 electronically to members with registered email addresses. For others, a weblink will be provided. The cut-off date for determining voting eligibility is August 13, 2026, with remote e-voting from August 17 to August 19, 2026. The record date for dividend is August 7, 2026. The AGM agenda includes adopting audited standalone and consolidated financial statements for FY 2025-26, declaring a dividend of ₹10 per equity share, and re-appointing directors Mr. Ashutosh Jain and Mr. Peeyush Jain.

Venus Remedies Ltd has released its annual report for FY 2025-26, outlining key resolutions for the upcoming 17th Annual General Meeting (AGM). The company proposes a final dividend of ₹5.20 per equity share for FY26. Additionally, the report details the non-reappointment of Director Mr. Divya Sehgal and the appointment of M/s. Batliboi & Purohit as Joint Statutory Auditors for a three-year term commencing FY27, with an annual remuneration of ₹40 Lakhs. The reappointment of Ms. Geeta Dutta Goel as Non-Executive, Independent Director is also on the agenda.

Venus Remedies Ltd has announced its 37th Annual General Meeting (AGM) will be held on Thursday, August 20, 2026, at 11:30 AM IST via Video Conferencing (VC) / Other Audio Visual Means (OAVM). The company will submit its Annual Report and Notice of AGM for the financial year 2025-26. The cut-off date for determining eligible shareholders for remote e-voting is August 13, 2026. Remote e-voting will be open from August 17 to August 19, 2026. The record date for dividend purposes is August 7, 2026. The agenda includes adopting the audited standalone and consolidated financial statements for FY 2025-26, declaring a dividend of ₹10 per equity share, and re-appointing directors Mr. Ashutosh Jain and Mr. Peeyush Jain.

Venus Remedies Limited's Board of Directors met on July 20, 2026, to approve the unaudited financial results for the quarter ended June 30, 2026 (Consolidated and Standalone). The board also approved revisions to the proposed alteration of the Memorandum of Association (MOA) and Articles of Association (AOA). These revisions aim to align the Object Clause with the Companies Act, 2013, and update it with current and proposed business activities, while maintaining the company's primary operations in the pharmaceutical sector. The revised MOA will be presented to members for approval via a Special Resolution at the upcoming 37th Annual General Meeting. The trading window for designated persons was closed from July 1, 2026, until 48 hours after the financial results declaration.

Venus Remedies Limited's Board of Directors met on July 20, 2026, to approve the unaudited financial results (Consolidated and Standalone) for the quarter ended June 30, 2026, along with the auditor's limited review report. The board also approved revisions to the proposed alteration of the Memorandum of Association (MOA), primarily to align the object clause with the Companies Act, 2013, and update it with current and proposed business activities in the pharmaceutical sector. The revised MOA will be presented to shareholders for approval via a special resolution at the upcoming 37th Annual General Meeting. The trading window for designated persons was closed from July 1, 2026, until 48 hours after the financial results declaration.

Venus Remedies Limited announced that its Board of Directors, in a meeting held on July 20, 2026, approved the unaudited financial results (Consolidated and Standalone) for the quarter ended June 30, 2026. The company also approved revisions to the proposed alteration of its Memorandum of Association (MOA) and Articles of Association (AOA) to align with the Companies Act, 2013, and current business practices. The revised MOA will be presented to shareholders for approval via a special resolution at the upcoming 37th Annual General Meeting. The trading window for designated persons remains closed until 48 hours after the declaration of financial results.